Providence Therapeutics develops personalized mRNA vaccines specifically targeting ovarian cancer, utilizing a robust mRNA Ecosystem for rapid therapeutic development. The company addresses the need for effective treatment options in oncology, particularly for patients with hard-to-treat cancers.
Funding
$8.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Ovarian cancer and other solid tumors present significant treatment challenges due to their complex biology and limited response to conventional therapies. Personalized cancer vaccines are difficult to develop rapidly and cost-effectively, hindering their accessibility for patients with specific tumor profiles. Infectious diseases and animal health also lack effective vaccine options.
Solution
Providence Therapeutics develops mRNA-based therapeutics and vaccines, leveraging a clinically proven mRNA ecosystem for rapid development and manufacturing. The company focuses on personalized cancer vaccines targeting solid tumors with precision antigens, as well as prophylactic and post-exposure vaccines for infectious diseases and animal health. Their mRNA platform and INTENT (TM) LNP platform facilitate the creation of tailored therapies, while their validated manufacturing platform ensures scalable production. Providence Therapeutics aims to address unmet needs in oncology and infectious diseases through its innovative mRNA technology.
Target Audience
The primary target audience includes patients with ovarian cancer and other solid tumors, individuals at risk of infectious diseases, and the animal health industry seeking prophylactic vaccine solutions.
Features
- mRNA Medicines Ecosystem: Agile and robust platform for rapid development of mRNA-based therapeutics.
- INTENT (TM) LNP Platform: Next-generation lipid nanoparticle (LNP) technology for efficient mRNA delivery.
- Validated Manufacturing Platform: Scalable manufacturing capabilities for clinical and commercial production.
- PTX-102: Precision medicine approach targeting solid tumors with precision antigens.
- PTX-103: Glioblastoma vaccine targeting common antigens.
- PTX-106: Personalized cancer vaccine development.
- PTX-202: Post-exposure vaccine for Rabies.
- PTX-203: Prophylactic vaccine for Shingles.
- PTX-301: Prophylactic vaccine for Highly Pathogenic Influenza in animal health.